All In Biotech

Drug Trial Radar · NCT05325645

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

A Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Investigate the Efficacy and Safety of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Jul 21, 2022

Primary completion

Sep 2027

Study completion Oct 2027

Sponsor

Sponsor type
Industry
Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
First posted
Apr 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia

Conditions

  • Acute Schizophrenia

Interventions

  • OPC-34712FUM/ Brexpiprazole fumarateDrug

    2 brexpiprazole QW tablets 24 mg (48 mg/dose) will be orally administered once weekly for 7weeks.(As an initial dose, one brexpiprazole QW tablet 24 mg and one placebo tablet will be orally administered (24 mg/dose))

  • PlaceboDrug

    Two placebo tablets will be orally administered once weekly for 7weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at last visit of the double-blind periodTime frame: Baseline and Week 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hayakawa Clinic

    Kure-shi, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.